Tissue repair and regeneration are fundamental biological processes that are constantly being challenged by injury and aging. When these mechanisms become dysregulated, they can lead to pathological scarring, organ failure or death. Indeed, in the developed world, it is thought that almost 45% of all deaths are ultimately attributable to some type of chronic fibroproliferative disease. Fibrosis affects nearly all tissues and organ systems. Diseases in which fibrosis is a major cause of morbidity and mortality include the interstitial lung diseases, liver cirrhosis, kidney disease, heart disease, systemic sclerosis, among others. Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients. Stem cell (SC)- or progenitor cells based tissue regeneration holds promise for treating many of these diseases. Recent advances include differentiation of pluripotent SCs (ESCs and iPSCs) into hepatic, intestinal, cardiac, and pancreatic cells that may be used to replace defective cells types. The goal of this meeting is to bring together academic researchers, clinicians, and members of the pharmaceutical industry to discuss the most recent advances in the fields of stem cell biology, tissue repair, organ regeneration and fibrosis and to identify key roadblocks that are slowing progress in each of these important areas. By bringing together a diverse group of researchers interested in all aspects of tissue repair and regeneration, the meeting will provide a more integrated perspective from basic disease mechanisms through to the more pragmatic challenges of clinical trial design.